The Function of Regulatory T Cells That Control Inflammatory Responses in the Colon Is Dependent on IL-10
| Phenotype of CD4+ T cells injected . | mAb treatment . | No or minimal colitis (0–1) . | Mild colitis (2) . | Severe colitis (3–5) . |
|---|---|---|---|---|
| RAG-2−/− recipients | ||||
| 4 × 105 CD45RBhigh | – | 8/41 (19.5%) | 7/41 | 26/41 (63.4%) |
| 4 × 105 CD45RBhigh | ||||
| + 2 × 105 WT CD45RBlow | – | 26/31 (83.8%) | 3/31 | 2/31 (6.4%) |
| 4 × 105 CD45RBhigh | ||||
| + 2 × 105 IL-10−/− CD45RBlow | – | 6/28 (21.4%) | 4/28 | 18/28 (64.2%) |
| 2 × 105 IL-10−/− CD45RBlow | – | 5/22 (22.7%) | 4/22 | 13/22 (59.0%) |
| C.B-17 SCID recipients | ||||
| 4 × 105 CD45RBhigh | – | 0/9 | 3/9 | 6/9 |
| 4 × 105 CD45RBhigh | ||||
| + 2 × 105 CD45RBlow | Isotype control | 6/7 | 1/7 | 0/7 |
| 4 × 105 CD45RBhigh | ||||
| + 2 × 105 CD45RBlow | Anti–IL-10 | 5/5 | 0/5 | 0/5 |
| 4 × 105 CD45RBhigh | ||||
| + 2 × 105 CD45RBlow | Anti–IL-10R | 0/8 | 0/8 | 8/8 |
| 4 × 105 CD45RBhigh | Anti–IL-10 + | |||
| + 2 × 105 CD45RBlow | Anti–IL-10R | 0/5 | 2/5 | 3/5 |
| Phenotype of CD4+ T cells injected . | mAb treatment . | No or minimal colitis (0–1) . | Mild colitis (2) . | Severe colitis (3–5) . |
|---|---|---|---|---|
| RAG-2−/− recipients | ||||
| 4 × 105 CD45RBhigh | – | 8/41 (19.5%) | 7/41 | 26/41 (63.4%) |
| 4 × 105 CD45RBhigh | ||||
| + 2 × 105 WT CD45RBlow | – | 26/31 (83.8%) | 3/31 | 2/31 (6.4%) |
| 4 × 105 CD45RBhigh | ||||
| + 2 × 105 IL-10−/− CD45RBlow | – | 6/28 (21.4%) | 4/28 | 18/28 (64.2%) |
| 2 × 105 IL-10−/− CD45RBlow | – | 5/22 (22.7%) | 4/22 | 13/22 (59.0%) |
| C.B-17 SCID recipients | ||||
| 4 × 105 CD45RBhigh | – | 0/9 | 3/9 | 6/9 |
| 4 × 105 CD45RBhigh | ||||
| + 2 × 105 CD45RBlow | Isotype control | 6/7 | 1/7 | 0/7 |
| 4 × 105 CD45RBhigh | ||||
| + 2 × 105 CD45RBlow | Anti–IL-10 | 5/5 | 0/5 | 0/5 |
| 4 × 105 CD45RBhigh | ||||
| + 2 × 105 CD45RBlow | Anti–IL-10R | 0/8 | 0/8 | 8/8 |
| 4 × 105 CD45RBhigh | Anti–IL-10 + | |||
| + 2 × 105 CD45RBlow | Anti–IL-10R | 0/5 | 2/5 | 3/5 |
RAG-2−/− or C.B-17 SCID mice were reconstituted with sorted CD4+ T cell subsets and treated for 8 wk with antibodies as indicated (2 mg the day after T cell reconstitution and 1 mg/wk thereafter for anti–IL-10 mAb and isotype control; 1 mg the day after T cell reconstitution and 0.5 mg/wk thereafter for anti–IL-10R mAb). 8–12 wk after reconstitution, mice were killed and colonic pathology was graded on a scale of 0–5 as described in Materials and Methods.